Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBIT (2018 - 2025)

Eton Pharmaceuticals' EBIT history spans 7 years, with the latest figure at $2.4 million for Q4 2025.

  • On a quarterly basis, EBIT fell 3.09% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$957000.0, a 19.63% decrease, with the full-year FY2025 number at -$957000.0, down 19.63% from a year prior.
  • EBIT hit $2.4 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • Over the last five years, EBIT for ETON hit a ceiling of $7.4 million in Q4 2022 and a floor of -$5.8 million in Q3 2021.
  • Historically, EBIT has averaged -$316900.0 across 5 years, with a median of -$1.1 million in 2022.
  • Biggest five-year swings in EBIT: skyrocketed 465.3% in 2022 and later crashed 367.78% in 2025.
  • Tracing ETON's EBIT over 5 years: stood at $1.3 million in 2021, then skyrocketed by 465.3% to $7.4 million in 2022, then crashed by 126.83% to -$2.0 million in 2023, then soared by 221.73% to $2.4 million in 2024, then fell by 3.09% to $2.4 million in 2025.
  • Business Quant data shows EBIT for ETON at $2.4 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.5 million in Q2 2025.